A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

PHASE3CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

May 6, 2022

Study Completion Date

May 6, 2022

Conditions
Dry Eye
Interventions
DRUG

0.25% Tanfanercept Ophthalmic Solution

Tanfanercept ophthalmic solution.

DRUG

Placebo

Placebo vehicle solution.

Trial Locations (10)

16066

Scott & Christie and Associates, PC, Cranberry Township

27529

Oculus Research, Inc., Garner

37072

Advancing Vision Research, LLC., Smyrna

40206

The Eye Care Institute - Butchertown Clinical Trials, Louisville

85032

Cornea & Cataract Consultants of Arizona, Phoenix

89052

Center For Sight, Henderson

91204

Global Research Management, Glendale

92663

Eye Research Foundation, Inc., Newport Beach

02767

Andover Eye Associates: Raynham, Raynham

02886

Andover Eye Associates: Warwick, Warwick

All Listed Sponsors
collaborator

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

lead

HanAll BioPharma Co., Ltd.

INDUSTRY